Join Clinical Trials
  • Login
  • Home
  • Clinical Trial Categories
  • Adults - 18 - 64
  • Mississippi


Menu

Choose Which Database to Search - Volunteer Database - Clinical Trial Database Create an Account - VOLUNTEER Accounts - RECRUITER Accounts Account Login - Volunteers Login - Recruiters Login Join a Clinical Trial Clinical Trials by Category Clinical Trials by Location Submit a Clinical Trial Frequently Asked Questions Contact Us Sitemap Blog

Categories

    Healthy Volunteers Adults - 18 - 64 Youths - Birth - 17 Seniors - 65 + Expanded Access Compensated Trials Clinical Trials by Condition Trials by Drug Type Trials for Rare Conditions

Recent Listings

  • Post your clinical trial on JoinClinicalTrials.com

    Ellijay, Georgia 30536
    United States

    Post your clinical trial on JoinClinicalTrials.com

    05-09-2019 01:01PM

JoinClinicalTrials.com

Jackson

Gulfport

Biloxi

Hattiesburg

Greenville

Meridian

Tupelo

Southaven

Vicksburg

Pascagoula


Results

Post your clinical trial on JoinClinicalTrials.com
Hot

Post your clinical trial on JoinClinicalTrials.com


Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

Results 1 - 1 of 1
  • <<
  • <
  • 1
  • >
  • >>

  • Effects of Immulina on Immune Measures
    NCT04071730
    Condition:   Effects of Immulina on Natural Killer Cells
    Intervention:   Dietary Supplement: Immulina Dietary Supplementation
    Sponsor:   University of Mississippi Medical Center
    Recruiting
  • Self-Sampling for Human Papillomavirus (HPV) Testing in African American Women - Mississippi Delta
    NCT03713710
    Condition:   Cervical Cancer
    Interventions:   Behavioral: Pap testing;   Behavioral: Choice
    Sponsors:   University of Alabama at Birmingham;   American Cancer Society, Inc.
    Recruiting
  • A Dose Escalation Study of Intravenous L-citrulline in Steady-state Sickle Cell Disease
    NCT02314689
    Condition:   Sickle Cell Disease
    Intervention:   Drug: Intravenous (IV) citrulline
    Sponsor:   Suvankar Majumdar
    Completed
  • Sensorimotor Training for Injury Prevention in Collegiate Soccer Players II
    NCT04036916
    Conditions:   Concussion, Mild;   Sport Injury
    Intervention:   Other: Virtual Reality Sensorimotor Training
    Sponsors:   University of Mississippi Medical Center;   University of West Alabama;   Mississippi College
    Enrolling by invitation
  • Telemedicine for PrEP Throughout Mississippi
    NCT03840382
    Condition:   HIV/AIDS
    Intervention:   Behavioral: Tele-PrEP Intervention
    Sponsors:   Rhode Island Hospital;   University of Mississippi Medical Center
    Not yet recruiting
  • FES Cycling and Nutritional Counseling for Battling Obesity After SCI
    NCT03810963
    Condition:   Spinal Cord Injuries
    Interventions:   Combination Product: HIIT-FES Cycling combined with Nutritional Counseling;   Other: Nutritional Counseling Only
    Sponsors:   William Carey University;   University of Southern Mississippi;   University of Mississippi Medical Center
    Completed
  • A Study to Allow Continued Treatment of Patients Who Have Participated in a Spectrum-Sponsored Poziotinib Study
    NCT03744715
    Conditions:   NSCLC;   Breast Cancer
    Intervention:   Drug: Poziotinib
    Sponsor:   Spectrum Pharmaceuticals, Inc
    Recruiting
  • Training for Injury Prevention in Collegiate Soccer Players
    NCT03594669
    Condition:   Athletic Injuries
    Intervention:   Other: Intervention
    Sponsors:   University of Mississippi Medical Center;   Mississippi College
    Completed
  • Pilot of Home Visitation Services for Patients With a Diabetes Diagnosis
    NCT03374098
    Condition:   Diabetes
    Interventions:   Behavioral: Home Visitiation;   Behavioral: Education
    Sponsors:   Delta Health Alliance;   University of Tennessee Health Science Center
    Active, not recruiting
  • Post-Market Study to Assess Outcomes of Patients Treated With AFX System Compared to Other EVAR Devices
    NCT02407457
    Condition:   Abdominal Aortic Aneurysm
    Interventions:   Device: AFX EVAR AAA Graft System;   Device: FDA Approved EVAR AAA Graft Systems
    Sponsor:   Endologix
    Active, not recruiting
  • PCORI-CER-1306-03385 Informed Decisions About Lung Cancer Screening
    NCT02286713
    Conditions:   Lung Cancer;   Smoking Cessation;   Tobacco Use Cessation
    Interventions:   Behavioral: Patient Decision Aid;   Behavioral: Standard Educational Information;   Behavioral: Follow-Up Assessments: Questionnaires
    Sponsors:   M.D. Anderson Cancer Center;   Patient-Centered Outcomes Research Institute
    Active, not recruiting
  • Cannabidiol for Drug Resistant Pediatric Epilepsy (Expanded Access Use)
    NCT03676049
    Condition:   Drug Resistant Epilepsy
    Intervention:   Drug: Cannabidiol
    Sponsor:   John
    Temporarily not available
  • MySTYLE: Online Family-based HIV Prevention for Non-heterosexual Black Adolescent Males in the South
    NCT03487796
    Conditions:   Hiv;   Adolescent Behavior;   Family Relations;   Sexual Orientation
    Interventions:   Behavioral: MySTYLE;   Other: Waitlist Control
    Sponsors:   Rhode Island Hospital;   University of Mississippi Medical Center
    Enrolling by invitation
  • A Phase 1 Study of Continuous Intravenous L-citrulline During Sickle Cell Pain Crisis or Acute Chest Syndrome
    NCT02697240
    Condition:   Sickle Cell Disease
    Intervention:   Drug: Intravenous citrulline
    Sponsor:   University of Mississippi Medical Center
    Completed
  • Levels of Bisphenol A in Urine and Saliva Following Placement of Composite Restorations
    NCT00339339
    Condition:   Dental Restorations
    Intervention:  
    Sponsor:   National Institute of Dental and Craniofacial Research (NIDCR)
    Completed
  • Return of Genomic Results and Aggregate Penetrance in Population-Based Cohorts
    NCT04196374
    Conditions:   Seemingly Healthy;   Genetic Predisposition to Disease
    Intervention:   Genetic: Genomic Sequencing
    Sponsors:   Brigham and Women's Hospital;   Framingham Heart Study;   Jackson Heart Study;   Broad Institute;   University of Mississippi Medical Center;   Boston University;   Partners HealthCare
    Not yet recruiting
  • LSI (Lesion Index) Workflow Observational Study
    NCT03906461
    Condition:   Paroxysmal Atrial Fibrillation
    Intervention:   Device: Radiofrequency Ablation
    Sponsor:   Abbott Medical Devices
    Recruiting
  • Speed of Robotic Leg Movements and Orthostatic Hypotension in Subacute SCI
    NCT04029974
    Conditions:   Spinal Cord Injuries;   Orthostatic Hypotension
    Intervention:   Device: ErigoPro
    Sponsor:   Methodist Rehabilitation Center
    Recruiting
  • HealthMindr App to Increase Pre-exposure Prophylaxis (PrEP) Uptake and Retention Among Men Who Have Sex With Men (MSM)
    NCT03763942
    Condition:   HIV Infections
    Interventions:   Behavioral: HealthMindr App;   Behavioral: Control App
    Sponsors:   Emory University;   National Institutes of Health (NIH);   National Institute on Drug Abuse (NIDA)
    Not yet recruiting
  • Amantadine for Treatment of Symptoms of the Post-traumatic Confusional State
    NCT00693121
    Conditions:   Traumatic Brain Injury;   Posttraumatic Confusional State;   Delirium
    Interventions:   Drug: Amantadine hydrochloride;   Drug: Placebo capsule
    Sponsors:   Methodist Rehabilitation Center;   U.S. Department of Education
    Completed
  • The DETECT HCV Screening Trial
    NCT04003454
    Condition:   Hepatitis C
    Intervention:   Other: HCV Screening
    Sponsors:   Denver Health and Hospital Authority;   Johns Hopkins University;   University of Mississippi Medical Center;   Boston University;   Boston Medical Center;   University of Cincinnati;   Alameda County Medical Center
    Not yet recruiting
  • A Mobile Gaming App to Improve ART Adherence for Youth
    NCT03760211
    Conditions:   Medication Adherence;   HIV/AIDS
    Interventions:   Behavioral: Multilevel Gaming Adherence Intervention;   Behavioral: Treatment as Usual +
    Sponsors:   Rhode Island Hospital;   University of Mississippi Medical Center;   Boston Medical Center
    Enrolling by invitation
  • Postoperative and Chronic Pain Genetic Spine Surgery Study
    NCT02998138
    Conditions:   Scoliosis;   Kyphosis;   Kyphoscoliosis
    Intervention:  
    Sponsor:   Children's Hospital Medical Center, Cincinnati
    Enrolling by invitation
  • An Investigation of Functional Improvements in the RHEO KNEE Compared to Hydraulic MPKs
    NCT04023578
    Conditions:   Prosthesis User;   Amputation
    Intervention:   Device: RHEO KNEE XC
    Sponsors:   Össur Ehf;   Baker Orthotics & Prosthetics;   Virginia Prosthetics & Orthotics;   Methodist Rehabilitation Center
    Completed
  • A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
    NCT03652077
    Conditions:   Cervical Cancer;   Gastric Cancer;   Stomach Cancer;   Gastroesophageal Junction Cancer;   Esophageal Cancer;   Hepatocellular Carcinoma;   Melanoma;   Uveal Melanoma;   Merkel Cell Carcinoma;   Mesothelioma;   MSI;   Non-small Cell Lung Cancer;   NSCLC;   Ovarian Cancer;   Squamous Cell Carcinoma of the Head and Neck;   Small Cell Lung Cancer;   Renal Cell Carcinoma;   RCC;   Triple-negative Breast Cancer;   Urothelial Carcinoma;   Mismatch Repair Deficiency
    Intervention:   Drug: INCAGN02390
    Sponsor:   Incyte Corporation
    Recruiting
  • Cardiac Magnetic Resonance Imaging Strategy for the Management of Patients With Acute Chest Pain and Detectable to Elevated Troponin
    NCT01931852
    Conditions:   Acute Coronary Syndrome;   Chest Pain
    Interventions:   Procedure: Cardiac MRI;   Other: ACC/AHA Guideline adherent care
    Sponsors:   Wake Forest University Health Sciences;   National Institutes of Health (NIH);   National Heart, Lung, and Blood Institute (NHLBI)
    Active, not recruiting
  • A Research Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC)
    NCT03394781
    Condition:   Primary Sclerosing Cholangitis
    Intervention:   Drug: DUR-928
    Sponsor:   Durect
    Terminated
  • Epidural Steroid Injection Versus Epidural Steroid Injection and Manual Physical Therapy and Exercise in the Management of Lumbar Spinal Stenosis
    NCT00786981
    Condition:   Lumbar Spinal Stenosis
    Interventions:   Other: Epidural steroid injection plus physical therapy;   Other: Epidural steroid injection
    Sponsors:   Franklin Pierce University;   University of Colorado, Denver
    Completed
  • A PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN
    NCT04032093
    Condition:   Respiratory Tract Infection
    Interventions:   Biological: RSV vaccine;   Biological: Placebo
    Sponsor:   Pfizer
    Recruiting
  • Phase 2B/3 Double-blinded Placebo-controlled
    NCT03107377
    Condition:   Chlamydia Trachomatis Infection
    Interventions:   Drug: Amphora gel;   Drug: Placebo
    Sponsors:   Evofem Inc.;   Clinical Research Management, Inc.
    Completed
  • Reoxygenation After Cardiac Arrest (REOX Study)
    NCT01881243
    Condition:   Cardiac Arrest
    Intervention:  
    Sponsors:   The Cooper Health System;   National Heart, Lung, and Blood Institute (NHLBI)
    Completed
  • Phoenix Post-Approval Registry - Using the Phoenix Atherectomy Systems
    NCT02475200
    Conditions:   Peripheral Arterial Disease;   Claudication;   Critical Limb Ischemia
    Intervention:   Device: Atherectomy
    Sponsor:   Volcano Corporation
    Enrolling by invitation
  • SDM for Stroke Prevention in Atrial Fibrillation
    NCT02905032
    Condition:   Atrial Fibrillation
    Intervention:   Behavioral: Decision Aid
    Sponsors:   Mayo Clinic;   Park Nicollet Clinic;   Hennepin County Medical Center, Minneapolis;   National Heart, Lung, and Blood Institute (NHLBI)
    Enrolling by invitation
  • Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
    NCT03851445
    Condition:   Previously Treated Non-Small Cell Lung Cancer
    Intervention:   Drug: Screening Platform
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
    NCT03499353
    Condition:   Early Breast Cancer
    Intervention:   Drug: TALAZOPARIB
    Sponsor:   Pfizer
    Recruiting
  • Firstline Pembrolizumab Alone or in Combination With Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
    NCT03793179
    Conditions:   Lung Non-Squamous Non-Small Cell Carcinoma;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8
    Interventions:   Drug: Carboplatin;   Biological: Pembrolizumab;   Drug: Pemetrexed
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers
    NCT03768414
    Conditions:   Stage III Distal Bile Duct Cancer AJCC v8;   Stage III Gallbladder Cancer AJCC v8;   Stage III Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIA Distal Bile Duct Cancer AJCC v8;   Stage IIIA Gallbladder Cancer AJCC v8;   Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIB Distal Bile Duct Cancer AJCC v8;   Stage IIIB Gallbladder Cancer AJCC v8;   Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IV Distal Bile Duct Cancer AJCC v8;   Stage IV Gallbladder Cancer AJCC v8;   Stage IV Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IVA Gallbladder Cancer AJCC v8;   Stage IVB Gallbladder Cancer AJCC v8;   Unresectable Extrahepatic Bile Duct Carcinoma;   Unresectable Gallbladder Carcinoma;   Unresectable Intrahepatic Cholangiocarcinoma
    Interventions:   Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Drug: Nab-paclitaxel
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
    NCT03418961
    Conditions:   Cardiotoxicity;   HER2/Neu Positive;   Metastatic Malignant Neoplasm in the Brain;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer AJCC v6 and v7
    Interventions:   Drug: Carvedilol;   Other: Laboratory Biomarker Analysis;   Other: Patient Observation
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
    NCT03723928
    Conditions:   Anatomic Stage IV Breast Cancer AJCC v8;   Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Positive;   Prognostic Stage IV Breast Cancer AJCC v8;   Elevated CA15-3 or CEA or CA27-29
    Interventions:   Other: Usual care disease monitoring;   Other: Serum Tumor Marker directed disease monitoring;   Other: Quality-of-Life Assessment;   Other: Anxiety Questionnaire Administration
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Tele-Exercise and Multiple Sclerosis
    NCT03117881
    Condition:   Multiple Sclerosis
    Interventions:   Behavioral: DirectCAM;   Behavioral: TeleCAM
    Sponsors:   University of Alabama at Birmingham;   Patient-Centered Outcomes Research Institute;   Lakeshore Foundation;   Tanner Foundation for Neurological Diseases
    Recruiting
  • Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
    NCT02834013
    Conditions:   Acinar Cell Carcinoma;   Adenoid Cystic Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Angiosarcoma;   Apocrine Neoplasm;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Basal Cell Carcinoma;   Bladder Adenocarcinoma;   Cervical Adenocarcinoma;   Cervical Clear Cell Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Desmoid-Type Fibromatosis;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Extramammary Paget Disease;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gallbladder Carcinoma;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Gastric Undifferentiated Carcinoma;   Gastrointestinal Stromal Tumor;   Gestational Trophoblastic Tumor;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Testicular Sex Cord-Stromal Tumor;   Metaplastic Breast Carcinoma;   Metastatic Malignant Neoplasm of Unknown Primary;   Minimally Invasive Lung Adenocarcinoma;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   PEComa;   Peritoneal Mesothelioma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Rare Disorder;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Solid Neoplasm;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Somatic-Type Malignancy;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Carcinoma
    Interventions:   Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy
    NCT02927249
    Condition:   Node Positive HER2 Negative Breast Cancer
    Interventions:   Other: Placebo;   Drug: Aspirin
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   United States Department of Defense;   Bayer;   Canadian Cancer Trials Group
    Recruiting
  • Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
    NCT03087708
    Conditions:   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
    Interventions:   Drug: Naloxegol;   Other: Placebo;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
    NCT02785952
    Conditions:   Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma AJCC v7
    Interventions:   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • Breast Cancer WEight Loss Study (BWEL Study)
    NCT02750826
    Condition:   Breast Carcinoma
    Interventions:   Other: Health Education Program;   Other: Weight Loss Intervention
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Division of Cancer Control;   NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP);   Canadian Cancer Trials Group
    Recruiting
  • Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
    NCT02595944
    Conditions:   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
    Intervention:   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
    NCT02595905
    Conditions:   Breast Carcinoma Metastatic in the Brain;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer AJCC v6 and v7;   Triple-Negative Breast Carcinoma
    Interventions:   Drug: Cisplatin;   Other: Laboratory Biomarker Analysis;   Other: Placebo Administration;   Drug: Veliparib
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
    NCT02954874
    Conditions:   Invasive Breast Carcinoma;   Stage 0 Breast Cancer AJCC v6 and v7;   Stage I Breast Cancer AJCC v7;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage II Breast Cancer AJCC v6 and v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Triple-Negative Breast Carcinoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Patient Observation;   Biological: Pembrolizumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
    NCT02465060
    Conditions:   Advanced Malignant Solid Neoplasm;   Bladder Carcinoma;   Breast Carcinoma;   Cervical Carcinoma;   Colon Carcinoma;   Colorectal Carcinoma;   Endometrial Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Glioma;   Head and Neck Carcinoma;   Kidney Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Lung Carcinoma;   Lymphoma;   Malignant Uterine Neoplasm;   Melanoma;   Ovarian Carcinoma;   Pancreatic Carcinoma;   Plasma Cell Myeloma;   Prostate Carcinoma;   Rectal Carcinoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Glioma;   Recurrent Head and Neck Carcinoma;   Recurrent Liver Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Plasma Cell Myeloma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Skin Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Refractory Lymphoma;   Refractory Malignant Solid Neoplasm;   Refractory Plasma Cell Myeloma;   Skin Carcinoma;   Thyroid Gland Carcinoma;   Uterine Corpus Cancer
    Interventions:   Drug: Adavosertib;   Drug: Afatinib;   Drug: Afatinib Dimaleate;   Drug: Binimetinib;   Drug: Capivasertib;   Drug: Copanlisib;   Drug: Copanlisib Hydrochloride;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Drug: Dasatinib;   Drug: Defactinib;   Drug: Defactinib Hydrochloride;   Drug: Erdafitinib;   Drug: FGFR Inhibitor AZD4547;   Drug: Ipatasertib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab;   Biological: Trastuzumab Emtansine;   Drug: Ulixertinib;   Drug: Vismodegib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Management of Tobacco Treatment Intervention in Reducing Surgical Complications in Patients With Newly Diagnosed Lung Cancer Who Smoke Cigarettes
    NCT02856581
    Condition:   Lung Carcinoma
    Interventions:   Drug: Varenicline;   Drug: Placebo;   Other: Tobacco Cessation Counseling
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Pfizer
    Active, not recruiting
  • Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
    NCT03578081
    Condition:   Malignant Neoplasm
    Interventions:   Drug: Palonosetron Hydrochloride;   Drug: Ondansetron Hydrochloride;   Drug: Dexamethasone;   Drug: Fosaprepitant Dimeglumine;   Drug: Olanzapine;   Other: Placebo
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
    NCT02194738
    Conditions:   Lung Adenocarcinoma;   Lung Large Cell Carcinoma;   Resectable Lung Non-Small Cell Carcinoma;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IB Lung Squamous Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage II Lung Squamous Cell Carcinoma AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIA Lung Squamous Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Squamous Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
    Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Biological: Nivolumab;   Other: Placebo Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
    NCT02193282
    Conditions:   EGFR Exon 19 Deletion Mutation;   EGFR NP_005219.2:p.L858R;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
    Interventions:   Other: Clinical Observation;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer
    NCT03244384
    Conditions:   Stage II Bladder Urothelial Carcinoma AJCC v6 and v7;   Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
    Interventions:   Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
    NCT02115282
    Conditions:   Breast Adenocarcinoma;   HER2/Neu Negative;   Locally Advanced Breast Carcinoma;   Metastatic Breast Carcinoma;   Recurrent Breast Carcinoma;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7
    Interventions:   Drug: Entinostat;   Drug: Exemestane;   Drug: Goserelin;   Drug: Goserelin Acetate;   Other: Placebo Administration;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)
    NCT02728596
    Conditions:   Febrile Neutropenia;   Stage 0 Breast Cancer;   Stage 0 Colorectal Cancer;   Stage 0 Non-Small Cell Lung Cancer;   Stage I Colorectal Cancer;   Stage IA Breast Cancer;   Stage IA Non-Small Cell Lung Carcinoma;   Stage IB Breast Cancer;   Stage IB Non-Small Cell Lung Carcinoma;   Stage IIA Breast Cancer;   Stage IIA Colorectal Cancer;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIB Breast Cancer;   Stage IIB Colorectal Cancer;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIC Colorectal Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Colorectal Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Colorectal Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Colorectal Cancer;   Stage IV Breast Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IVA Colorectal Cancer;   Stage IVB Colorectal Cancer
    Interventions:   Other: Preventive Intervention;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Patient-Centered Outcomes Research Institute
    Recruiting
  • Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy
    NCT01901094
    Conditions:   Stage II Breast Cancer;   Stage IIIA Breast Cancer
    Interventions:   Procedure: Axillary Lymph Node Dissection (ALND);   Radiation: Nodal Radiation Therapy;   Radiation: Axillary Radiation Therapy
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Suspended
  • Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
    NCT02488967
    Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
    Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Dose Escalation Safety Study of TMB-365 in HIV-1 Infected Participants
    NCT04027387
    Condition:   HIV-1-infection
    Intervention:   Biological: TMB-365
    Sponsors:   TaiMed Biologics Inc.;   Westat
    Not yet recruiting
  • S0820, Adenoma and Second Primary Prevention Trial
    NCT01349881
    Condition:   Colorectal Neoplasms
    Interventions:   Drug: Eflornithine placebo & sulindac placebo;   Drug: eflornithine & sulindac placebo;   Drug: Eflornithine placebo & sulindac;   Drug: Eflornithine plus sulindac
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Cancer Prevention Pharmaceuticals, Inc.
    Recruiting
  • Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
    NCT02154490
    Conditions:   Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma AJCC v7
    Interventions:   Drug: Docetaxel;   Biological: Durvalumab;   Drug: Erlotinib Hydrochloride;   Drug: FGFR Inhibitor AZD4547;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Palbociclib;   Other: Pharmacological Study;   Biological: Rilotumumab;   Drug: Talazoparib;   Drug: Taselisib;   Biological: Tremelimumab
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
    NCT01953588
    Conditions:   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Invasive Ductal Breast Carcinoma;   Invasive Lobular Breast Carcinoma;   Recurrent Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Drug: fulvestrant;   Drug: anastrozole
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Active, not recruiting
  • Ruxolitinib Phosphate and Dasatinib or Nilotinib in Treating Patients With Chronic Myeloid Leukemia
    NCT03654768
    Condition:   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    Interventions:   Drug: Dasatinib;   Other: Laboratory Biomarker Analysis;   Drug: Nilotinib;   Drug: Ruxolitinib Phosphate
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
    NCT03233711
    Conditions:   Anal Basaloid Carcinoma;   Anal Canal Cloacogenic Carcinoma;   Anal Margin Squamous Cell Carcinoma;   Stage IIB Anal Cancer AJCC v8;   Stage IIIA Anal Cancer AJCC v8;   Stage IIIB Anal Cancer AJCC v8;   Stage IIIC Anal Cancer AJCC v8
    Interventions:   Biological: Nivolumab;   Other: Patient Observation
    Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Recruiting
  • Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
    NCT02997228
    Conditions:   Colorectal Adenocarcinoma;   Stage IV Colorectal Cancer AJCC v7;   Stage IVA Colorectal Cancer AJCC v7;   Stage IVB Colorectal Cancer AJCC v7
    Interventions:   Drug: Atezolizumab;   Biological: Bevacizumab;   Drug: Fluorouracil;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Recruiting
  • Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer
    NCT02921256
    Conditions:   Rectal Adenocarcinoma;   Stage II Rectal Cancer AJCC v7;   Stage III Rectal Cancer AJCC v7
    Interventions:   Drug: Capecitabine;   Drug: Fluorouracil;   Radiation: Intensity-Modulated Radiation Therapy;   Drug: Leucovorin;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Biological: Pembrolizumab;   Drug: Veliparib
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Suspended
  • Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil
    NCT02822573
    Conditions:   Cognitive Dysfunction;   Memory Impairment
    Interventions:   Drug: Donepezil 5 mg;   Drug: Placebo
    Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
    Recruiting
  • Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
    NCT01272037
    Conditions:   Ductal Breast Carcinoma In Situ;   Invasive Breast Carcinoma;   Multicentric Breast Carcinoma;   Multifocal Breast Carcinoma;   Synchronous Bilateral Breast Carcinoma
    Interventions:   Drug: Anastrozole;   Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Other: Quality-of-Life Assessment;   Drug: Systemic Chemotherapy;   Drug: Tamoxifen Citrate
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
    NCT00632853
    Condition:   Lung Cancer
    Interventions:   Radiation: Standard Radiation Dose Therapy;   Drug: cisplatin;   Drug: etoposide;   Radiation: High Radiation Dose Therapy;   Drug: carboplatin
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS)
    NCT00373685
    Condition:   Osteoarthritis
    Interventions:   Drug: Celecoxib;   Drug: Any commercially available NSAID with the indication for osteoarthritis
    Sponsor:   Pfizer
    Completed
  • Evaluation of Efficacy and Safety of Roxadustat in the Treatment of Anemia in Stable Dialysis Subjects
    NCT02273726
    Condition:   CKD Anemia in Stable Dialysis Patients
    Interventions:   Drug: Epoetin Alfa;   Drug: FG-4592
    Sponsors:   FibroGen;   Astellas Pharma Europe B.V.;   AstraZeneca
    Completed
  • S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer
    NCT02164916
    Condition:   Colorectal Cancer
    Interventions:   Biological: cetuximab;   Drug: irinotecan hydrochloride;   Drug: vemurafenib
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Roche-Genentech
    Active, not recruiting
  • Safety Follow-up Study in Subjects With Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms
    NCT00443274
    Condition:   Breast Implant
    Interventions:   Other: NBIR Placeholder;   Device: 410 Arm;   Device: BIFs
    Sponsor:   Allergan
    Active, not recruiting
  • Safety and Efficacy Study for Treatment of Anemia in ESRD Newly Initiated Dialysis Patients
    NCT02052310
    Condition:   Anemia in Incident Dialysis Patients
    Interventions:   Drug: FG-4592 (roxadustat);   Drug: Epoetin Alfa
    Sponsors:   FibroGen;   Astellas Pharma Europe B.V.;   AstraZeneca
    Completed
  • Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy
    NCT00769379
    Condition:   Ductal Breast Carcinoma In Situ
    Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Trastuzumab;   Radiation: Whole Breast Irradiation
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Active, not recruiting
  • Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
    NCT00310180
    Conditions:   Breast Adenocarcinoma;   Estrogen Receptor and/or Progesterone Receptor Positive;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage IIIB Breast Cancer AJCC v7
    Interventions:   Drug: Anastrozole;   Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Other: Quality-of-Life Assessment;   Radiation: Radiation Therapy;   Drug: Tamoxifen Citrate
    Sponsors:   National Cancer Institute (NCI);   American College of Surgeons;   Cancer and Leukemia Group B;   NSABP Foundation Inc;   NCIC Clinical Trials Group;   North Central Cancer Treatment Group;   Southwest Oncology Group
    Active, not recruiting
  • Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
    NCT00588770
    Conditions:   Recurrent Hypopharyngeal Squamous Cell Carcinoma;   Recurrent Laryngeal Squamous Cell Carcinoma;   Recurrent Laryngeal Verrucous Carcinoma;   Recurrent Lip and Oral Cavity Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary;   Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Recurrent Oral Cavity Verrucous Carcinoma;   Recurrent Oropharyngeal Squamous Cell Carcinoma;   Recurrent Salivary Gland Carcinoma;   Salivary Gland Squamous Cell Carcinoma;   Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary;   Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7;   Stage IV Major Salivary Gland Cancer AJCC v7;   Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7;   Stage IVA Laryngeal Verrucous Carcinoma AJCC v7;   Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7;   Stage IVA Major Salivary Gland Cancer AJCC v7;   Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7;   Stage IVA Oral Cavity Cancer AJCC v6 and v7;   Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7;   Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7;   Stage IVB Laryngeal Verrucous Carcinoma AJCC v7;   Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7;   Stage IVB Major Salivary Gland Cancer AJCC v7;   Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7;   Stage IVB Oral Cavity Cancer AJCC v6 and v7;   Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7;   Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7;   Stage IVC Laryngeal Verrucous Carcinoma AJCC v7;   Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7;   Stage IVC Major Salivary Gland Cancer AJCC v7;   Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7;   Stage IVC Oral Cavity Cancer AJCC v6 and v7;   Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7;   Tongue Carcinoma
    Interventions:   Biological: Bevacizumab;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Docetaxel;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
    NCT01674140
    Condition:   Breast Cancer
    Interventions:   Drug: anastrozole;   Drug: everolimus;   Drug: exemestane;   Drug: goserelin acetate;   Drug: letrozole;   Drug: leuprolide acetate;   Drug: tamoxifen citrate;   Other: placebo
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • Cardiovascular Inflammation Reduction Trial
    NCT01594333
    Condition:   Cardiovascular Disease
    Interventions:   Drug: Methotrexate;   Drug: Placebo
    Sponsors:   Brigham and Women's Hospital;   National Heart, Lung, and Blood Institute (NHLBI)
    Completed
  • A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B
    NCT03861273
    Condition:   Hemophilia B
    Intervention:   Biological: PF-06838435/ fidanacogene elaparvovec
    Sponsor:   Pfizer
    Recruiting
  • Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
    NCT00217737
    Conditions:   Colon Mucinous Adenocarcinoma;   Colon Signet Ring Cell Adenocarcinoma;   Lynch Syndrome;   Stage IIA Colon Cancer AJCC v7;   Stage IIB Colon Cancer AJCC v7;   Stage IIC Colon Cancer AJCC v7
    Interventions:   Biological: Bevacizumab;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
    NCT03439254
    Conditions:   Compensated Cirrhosis;   Nonalcoholic Steatohepatitis
    Interventions:   Drug: Obeticholic acid (10 mg);   Drug: Obeticholic acid (10 mg to 25 mg);   Drug: Placebo
    Sponsor:   Intercept Pharmaceuticals
    Recruiting
  • Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer
    NCT03382561
    Conditions:   Extensive Stage Lung Small Cell Carcinoma;   Recurrent Lung Small Cell Carcinoma
    Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Combination Chemotherapy in Treating Women With Breast Cancer
    NCT00003519
    Condition:   Breast Cancer
    Interventions:   Drug: cyclophosphamide;   Drug: docetaxel;   Drug: doxorubicin hydrochloride
    Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   Southwest Oncology Group;   North Central Cancer Treatment Group;   Cancer and Leukemia Group B
    Completed
  • AURORA: Phase 3 Study for the Efficacy and Safety of CVC for the Treatment of Liver Fibrosis in Adults With NASH
    NCT03028740
    Condition:   Nonalcoholic Steatohepatitis
    Interventions:   Drug: Cenicriviroc;   Drug: Placebo
    Sponsor:   Tobira Therapeutics, Inc.
    Recruiting
  • Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
    NCT02942407
    Conditions:   Atrial Fibrillation;   End Stage Renal Disease
    Interventions:   Drug: apixaban;   Drug: warfarin
    Sponsors:   Christopher Granger, MD;   Bristol-Myers Squibb
    Completed
  • Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
    NCT02887183
    Condition:   Heart Failure
    Intervention:   Drug: LCZ696 (sacubitril/valsartan)
    Sponsor:   Novartis Pharmaceuticals
    Completed
  • A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen
    NCT02066636
    Condition:   Non Small Cell Lung Cancer (NSCLC)
    Intervention:   Drug: Nivolumab
    Sponsor:   Bristol-Myers Squibb
    Active, not recruiting
  • Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction
    NCT01920711
    Condition:   Heart Failure With Preserved Ejection Fraction
    Interventions:   Drug: LCZ696;   Drug: Valsartan
    Sponsor:   Novartis Pharmaceuticals
    Completed
  • Advance Cardiac Resynchronization Therapy (CRT) Registry
    NCT01805154
    Condition:   Heart Failure
    Intervention:   Device: CRT Patients
    Sponsor:   Abbott Medical Devices
    Completed
  • Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
    NCT01015833
    Conditions:   Advanced Adult Hepatocellular Carcinoma;   Recurrent Hepatocellular Carcinoma;   Stage III Hepatocellular Carcinoma AJCC v7;   Stage IIIA Hepatocellular Carcinoma AJCC v7;   Stage IIIB Hepatocellular Carcinoma AJCC v7;   Stage IIIC Hepatocellular Carcinoma AJCC v7;   Stage IV Hepatocellular Carcinoma AJCC v7;   Stage IVA Hepatocellular Carcinoma AJCC v7;   Stage IVB Hepatocellular Carcinoma AJCC v7;   Unresectable Hepatocellular Carcinoma
    Interventions:   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Drug: Sorafenib Tosylate
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
    NCT00977574
    Conditions:   Endometrial Adenocarcinoma;   Endometrial Adenosquamous Carcinoma;   Endometrial Clear Cell Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Recurrent Uterine Corpus Carcinoma;   Stage IIIA Uterine Corpus Cancer AJCC v7;   Stage IIIB Uterine Corpus Cancer AJCC v7;   Stage IIIC Uterine Corpus Cancer AJCC v7;   Stage IVA Uterine Corpus Cancer AJCC v7;   Stage IVB Uterine Corpus Cancer AJCC v7
    Interventions:   Biological: Bevacizumab;   Drug: Carboplatin;   Drug: Ixabepilone;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Drug: Temsirolimus
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Active, not recruiting
  • Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
    NCT00942331
    Conditions:   Advanced Urothelial Carcinoma;   Metastatic Bladder Urothelial Carcinoma;   Metastatic Prostate Carcinoma;   Metastatic Renal Pelvis Urothelial Carcinoma;   Metastatic Ureter Urothelial Carcinoma;   Metastatic Urethral Urothelial Carcinoma;   Metastatic Urothelial Carcinoma;   Stage IV Bladder Urothelial Carcinoma AJCC v7;   Stage IV Prostate Cancer AJCC v7;   Stage IV Renal Pelvis Cancer AJCC v7;   Stage IV Ureter Cancer AJCC v7;   Stage IV Urethral Cancer AJCC v7;   Unresectable Urothelial Carcinoma
    Interventions:   Biological: Bevacizumab;   Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
    NCT00644228
    Conditions:   DS Stage I Plasma Cell Myeloma;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma
    Interventions:   Drug: Bortezomib;   Drug: Dexamethasone;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
    NCT00565851
    Conditions:   Clear Cell Adenocarcinoma;   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Fallopian Tube Undifferentiated Carcinoma;   Mucinous Adenocarcinoma;   Ovarian Brenner Tumor;   Ovarian Clear Cell Adenocarcinofibroma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Undifferentiated Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Carcinoma
    Interventions:   Biological: Bevacizumab;   Drug: Carboplatin;   Drug: Docetaxel;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Active, not recruiting
  • ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
    NCT00490139
    Condition:   Neoplasms, Breast
    Interventions:   Drug: Lapatinib;   Biological: Trastuzumab
    Sponsors:   Novartis Pharmaceuticals;   North Central Cancer Treatment Group;   National Cancer Institute (NCI);   Breast International Group;   Canadian Cancer Trials Group
    Active, not recruiting
  • An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
    NCT00791700
    Condition:   Human Immunodeficiency Virus
    Intervention:   Drug: Maraviroc
    Sponsors:   ViiV Healthcare;   Pfizer
    Active, not recruiting
  • A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)
    NCT04166773
    Condition:   Nonalcoholic Steatohepatitis
    Interventions:   Drug: Tirzepatide;   Drug: Placebo
    Sponsor:   Eli Lilly and Company
    Recruiting
  • A Phase 2b Study of Icosabutate in Fatty Liver Disease
    NCT04052516
    Condition:   Non Alcoholic Steatohepatitis (NASH)
    Interventions:   Drug: Icosabutate;   Drug: Placebo
    Sponsor:   NorthSea Therapeutics B.V.
    Recruiting
  • Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma
    NCT03994627
    Condition:   Soft Tissue Sarcoma
    Intervention:   Drug: Olaratumab
    Sponsor:   Eli Lilly and Company
    Available
  • Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)
    NCT03971474
    Conditions:   Recurrent Lung Non-Small Cell Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
    Interventions:   Drug: Docetaxel;   Drug: Gemcitabine;   Drug: Gemcitabine Hydrochloride;   Biological: Pembrolizumab;   Drug: Pemetrexed;   Drug: Pemetrexed Disodium;   Biological: Ramucirumab
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
    NCT03900429
    Condition:   NASH - Nonalcoholic Steatohepatitis
    Interventions:   Drug: MGL-3196;   Drug: Placebo
    Sponsor:   Madrigal Pharmaceuticals, Inc.
    Recruiting
  • Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
    NCT03793166
    Conditions:   Clear Cell Renal Cell Carcinoma;   Metastatic Malignant Neoplasm in Lymph Node;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Malignant Neoplasm in the Soft Tissues;   Metastatic Malignant Neoplasm in the Viscera;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Renal Cell Cancer AJCC v8
    Interventions:   Drug: Cabozantinib;   Biological: Ipilimumab;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • To Evaluate the Safety and Tolerability of Atogepant 10mg, 30 mg and 60 mg Once a Day for the Prevention of Migraine in Participants With Episodic Migraine
    NCT03777059
    Condition:   Episodic Migraine
    Interventions:   Drug: Atogepant 30 mg;   Drug: Atogepant 60 mg;   Drug: Placebo;   Drug: Atogepant 10 mg
    Sponsor:   Allergan
    Recruiting
  • Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery
    NCT03698019
    Conditions:   Acral Lentiginous Melanoma;   Clinical Stage III Cutaneous Melanoma AJCC v8;   Clinical Stage IV Cutaneous Melanoma AJCC v8;   Mucosal Melanoma;   Pathologic Stage III Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIA Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIB Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIC Cutaneous Melanoma AJCC v8;   Pathologic Stage IIID Cutaneous Melanoma AJCC v8;   Pathologic Stage IV Cutaneous Melanoma AJCC v8
    Interventions:   Biological: Pembrolizumab;   Procedure: Therapeutic Conventional Surgery
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • ROMAN: A Study to Investigate the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer
    NCT03689712
    Condition:   Oral Mucositis
    Interventions:   Drug: GC4419;   Drug: Placebo
    Sponsor:   Galera Therapeutics, Inc.
    Recruiting
  • A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis.
    NCT03682705
    Condition:   Rheumatoid Arthritis (RA)
    Interventions:   Drug: Upadacitinib;   Drug: ABBV-105;   Drug: Upadacitinib placebo;   Drug: ABBV-105 placebo
    Sponsor:   AbbVie
    Recruiting
  • A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Subjects With Major Depressive Disorder
    NCT03672175
    Condition:   Major Depressive Disorder
    Interventions:   Drug: SAGE-217;   Drug: Placebo
    Sponsor:   Sage Therapeutics
    Active, not recruiting
  • Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
    NCT03662204
    Conditions:   Breast Cancer;   Lung Cancer;   Colorectal Cancer;   Prostate Cancer;   Bladder Cancer;   Uterine Cancer;   Kidney Cancer;   Renal Pelvis Cancer;   Pancreatic Cancer;   Liver Cancer;   Stomach Cancer;   Ovarian Cancer;   Esophageal Cancer
    Intervention:   Other: Blood Sample Collection
    Sponsor:   Exact Sciences Corporation
    Recruiting
  • An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis [EXPEDITION]
    NCT03616821
    Conditions:   Colitis;   Ulcerative;   IBD
    Interventions:   Drug: Brazikumab;   Drug: Vedolizumab;   Drug: Placebo
    Sponsor:   Allergan
    Recruiting
  • ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
    NCT03602560
    Condition:   Primary Biliary Cholangitis
    Interventions:   Drug: seladelpar 5-10 mg;   Drug: seladelpar 10 mg;   Drug: Placebo
    Sponsor:   CymaBay Therapeutics, Inc.
    Suspended
  • An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease
    NCT03599622
    Conditions:   Granulomatous Colitis;   Crohn's Disease;   Crohn's Enteritis;   Granulomatous Enteritis
    Interventions:   Drug: BMS-986165;   Other: Placebo
    Sponsor:   Bristol-Myers Squibb
    Recruiting
  • Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer
    NCT03598257
    Condition:   Inflammatory Breast Carcinoma
    Interventions:   Drug: Olaparib;   Radiation: Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001)
    NCT03594058
    Condition:   Overactive Bladder
    Interventions:   Drug: Solabegron modified release tablets, low dose;   Drug: Solabegron modified release tablets, high dose;   Drug: Matching Placebo
    Sponsor:   Velicept Therapeutics, Inc.
    Completed
  • Efficacy and Safety of Intravenous Neridronic Acid in CRPS
    NCT03530345
    Condition:   Complex Regional Pain Syndrome (CRPS)
    Interventions:   Drug: Neridronic acid;   Drug: Placebo
    Sponsor:   Grünenthal GmbH
    Terminated
  • A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men
    NCT03518034
    Conditions:   Hypogonadism;   Cardiovascular Diseases
    Interventions:   Drug: Testosterone;   Drug: Placebo
    Sponsors:   AbbVie;   Acerus Pharmaceuticals Corporation;   Allergan Sales, LLC;   Endo Pharmaceuticals;   Upsher-Smith Laboratories
    Recruiting
  • Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
    NCT03444870
    Condition:   Alzheimer Disease
    Interventions:   Drug: Gantenerumab;   Drug: Placebo
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma
    NCT03428217
    Conditions:   Advanced Renal Cell Carcinoma;   Metastatic Renal Cell Carcinoma
    Interventions:   Drug: CB-839;   Drug: Cabozantinib;   Drug: Placebo
    Sponsor:   Calithera Biosciences, Inc
    Active, not recruiting
  • A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)
    NCT03422653
    Condition:   Uremic Pruritus
    Interventions:   Drug: CR845 0.5 mcg/kg;   Drug: Placebo
    Sponsor:   Cara Therapeutics, Inc.
    Active, not recruiting
  • A Phase 3 STudy of CaPRe In LOwering Very hiGh TriglYcerides (TRILOGY 1)
    NCT03398005
    Condition:   Hypertriglyceridemia
    Interventions:   Drug: CaPre;   Drug: Placebo
    Sponsor:   Acasti Pharma Inc.
    Active, not recruiting
  • Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC
    NCT03326674
    Condition:   Breast Cancer
    Interventions:   Drug: Tesetaxel and Capecitabine;   Drug: Capecitabine
    Sponsor:   Odonate Therapeutics, Inc.
    Active, not recruiting
  • Antibiotic Prophylaxis in Patients Undergoing Elective TKA- Multi-center Trial
    NCT03283878
    Conditions:   Arthropathy of Knee;   Antibiotic Prophylaxis
    Intervention:   Drug: Cefazolin
    Sponsors:   Duke University;   American Association of Hip and Knee Society
    Recruiting
  • Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)
    NCT03248882
    Conditions:   Nonalcoholic Fatty Liver Disease;   Nonalcoholic Steatohepatitis
    Interventions:   Drug: Placebo;   Drug: PF-05221304
    Sponsor:   Pfizer
    Completed
  • XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients.
    NCT03218787
    Condition:   Coronary Artery Lesions
    Interventions:   Device: XIENCE;   Drug: DAPT
    Sponsor:   Abbott Medical Devices
    Active, not recruiting
  • A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)
    NCT03114657
    Condition:   Alzheimer's Disease
    Interventions:   Drug: Crenezumab;   Drug: Placebo
    Sponsor:   Hoffmann-La Roche
    Completed
  • Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial
    NCT03108456
    Conditions:   Coronary Artery Disease;   Ischemic Heart Disease;   Non ST Segment Elevation Myocardial Infarction
    Interventions:   Device: Orbital Atherectomy;   Device: Balloon
    Sponsors:   Cardiovascular Systems Inc;   Cardiovascular Research Foundation, New York
    Recruiting
  • Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
    NCT03092674
    Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts-2
    Interventions:   Drug: Azacitidine;   Drug: Cytarabine;   Drug: Decitabine;   Other: Laboratory Biomarker Analysis;   Drug: Midostaurin;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Suspended
  • Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
    NCT03055013
    Conditions:   Metastatic Malignant Neoplasm in Lymph Node;   Metastatic Malignant Neoplasm in the Adrenal Gland;   Metastatic Malignant Neoplasm in the Lung;   Metastatic Malignant Neoplasm in the Pancreas;   Metastatic Malignant Neoplasm in the Skin;   Metastatic Malignant Neoplasm in the Soft Tissues;   Metastatic Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage II Renal Cell Cancer AJCC v7;   Stage III Renal Cell Cancer AJCC v7;   Unclassified Renal Cell Carcinoma
    Interventions:   Procedure: Conventional Surgery;   Biological: Nivolumab;   Other: Patient Observation;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Recruiting
  • A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
    NCT03038100
    Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Neoplasms
    Interventions:   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Atezolizumab;   Drug: Bevacizumab;   Drug: Atezolizumab Placebo
    Sponsors:   Hoffmann-La Roche;   GOG Foundation;   European Network of Gynaecological Oncological Trial Groups (ENGOT)
    Active, not recruiting
  • Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis
    NCT03025308
    Condition:   RheumatoId Arthritis
    Interventions:   Drug: Filgotinib;   Drug: Placebo to match filgotinib
    Sponsors:   Gilead Sciences;   Galapagos NV
    Active, not recruiting
  • Registrational Study With Omecamtiv Mecarbil/AMG 423 to Treat Chronic Heart Failure With Reduced Ejection Fraction
    NCT02929329
    Condition:   Heart Failure
    Interventions:   Drug: Omecamtiv Mecarbil;   Drug: Placebo
    Sponsors:   Amgen;   Cytokinetics;   Servier
    Active, not recruiting
  • Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI
    NCT02924727
    Condition:   Acute Myocardial Infarction
    Interventions:   Drug: LCZ696 (sacubitril/valsartan);   Drug: Ramipril;   Drug: Placebo of LCZ696;   Drug: Placebo of ramipril;   Drug: Valsartan;   Drug: Placebo of valsartan
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  • FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
    NCT02890355
    Conditions:   Metastatic Pancreatic Adenocarcinoma;   Recurrent Pancreatic Carcinoma;   Stage IV Pancreatic Cancer AJCC v6 and v7
    Interventions:   Drug: Fluorouracil;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Veliparib
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
    NCT02889796
    Condition:   Rheumatoid Arthritis
    Interventions:   Drug: Filgotinib;   Drug: Placebo to match filgotinib;   Drug: Adalimumab;   Drug: Placebo to match adalimumab;   Drug: MTX
    Sponsors:   Gilead Sciences;   Galapagos NV
    Completed
  • Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy
    NCT02886728
    Condition:   Rheumatoid Arthritis
    Interventions:   Drug: Filgotinib;   Drug: Placebo to match filgotinib;   Drug: MTX;   Drug: Placebo to match MTX
    Sponsors:   Gilead Sciences;   Galapagos NV
    Completed
  • Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)
    NCT02879305
    Condition:   Anaemia
    Interventions:   Drug: Daprodustat;   Drug: rhEPO;   Drug: Placebo;   Drug: Iron therapy
    Sponsor:   GlaxoSmithKline
    Active, not recruiting
  • Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
    NCT02876835
    Condition:   Anaemia
    Interventions:   Drug: Daprodustat;   Drug: Darbepoetin alfa;   Drug: Placebo;   Drug: Iron Therapy
    Sponsor:   GlaxoSmithKline
    Recruiting
  • An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine
    NCT02873221
    Condition:   Migraine, With or Without Aura
    Interventions:   Drug: Ubrogepant;   Drug: Placebo-matching Ubrogepant;   Drug: Usual Care
    Sponsor:   Allergan
    Completed
  • Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
    NCT02730377
    Conditions:   Diabetes;   Diabetes Mellitus, Type 2
    Interventions:   Drug: liraglutide;   Drug: alpha-glucosidase inhibitors;   Drug: DPP-4 inhibitors;   Drug: meglitinides;   Drug: SGLT-2 inhibitors;   Drug: sulphonylurea;   Drug: thiazolidinediones
    Sponsor:   Novo Nordisk A/S
    Completed
  • A Gene Therapy Study for Hemophilia B
    NCT02484092
    Condition:   Hemophilia B
    Intervention:   Biological: SPK-9001
    Sponsor:   Pfizer
    Active, not recruiting
  • Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION)
    NCT02615002
    Condition:   Alzheimer's Disease
    Interventions:   Drug: Piromelatine;   Drug: Placebo
    Sponsor:   Neurim Pharmaceuticals Ltd.
    Active, not recruiting
  • A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
    NCT02574078
    Condition:   Non-Small Cell Lung Cancer
    Interventions:   Drug: Nivolumab;   Drug: Bevacizumab;   Drug: Pemetrexed;   Other: Best Supportive Care;   Drug: nab-Paclitaxel;   Drug: Paclitaxel;   Drug: Docetaxel;   Drug: Gemcitabine;   Drug: Erlotinib;   Drug: Crizotinib;   Drug: Carboplatin
    Sponsor:   Bristol-Myers Squibb
    Active, not recruiting
  • Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.
    NCT02554890
    Condition:   Acute Heart Failure
    Interventions:   Drug: sacubitril/valsartan (LCZ696);   Drug: Enalapril;   Drug: sacubitril/valsartan (LCZ696) matching placebo;   Drug: enalapril matching placebo
    Sponsor:   Novartis Pharmaceuticals
    Completed
  • Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee
    NCT02528188
    Conditions:   Chronic Pain;   Osteoarthritis, Hip;   Osteoarthritis, Knee
    Interventions:   Drug: NSAID;   Biological: Tanezumab 2.5 mg;   Biological: Tanezumab 5 mg
    Sponsor:   Pfizer
    Completed
  • Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities
    NCT02504216
    Condition:   Peripheral Artery Disease
    Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban-Placebo
    Sponsors:   Bayer;   Janssen Research & Development, LLC;   Colorado Prevention Center
    Active, not recruiting
  • Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
    NCT02446600
    Conditions:   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fallopian Tube Undifferentiated Carcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Tumor;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Tumor;   Ovarian Transitional Cell Carcinoma;   Ovarian Undifferentiated Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Ovarian Endometrioid Adenocarcinoma;   Recurrent Primary Peritoneal Carcinoma
    Interventions:   Drug: Carboplatin;   Drug: Cediranib Maleate;   Drug: Gemcitabine;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment
    Sponsors:   National Cancer Institute (NCI);   AstraZeneca;   NRG Oncology
    Active, not recruiting
  • SPYRAL HTN-ON MED Study
    NCT02439775
    Conditions:   Hypertension;   Vascular Diseases;   Cardiovascular Diseases
    Interventions:   Device: Symplicity Spyral™ multi-electrode renal denervation system;   Procedure: Sham Procedure
    Sponsor:   Medtronic Vascular
    Recruiting
  • SPYRAL PIVOTAL - SPYRAL HTN-OFF MED Study
    NCT02439749
    Conditions:   Hypertension;   Vascular Diseases;   Cardiovascular Diseases
    Interventions:   Device: Symplicity Spyral™ multi-electrode renal denervation system;   Procedure: Sham Procedure
    Sponsor:   Medtronic Vascular
    Recruiting
  • A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
    NCT02367781
    Condition:   Carcinoma, Non-Squamous Non-Small Cell Lung
    Interventions:   Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody;   Drug: Carboplatin;   Drug: Nab-Paclitaxel;   Drug: Pemetrexed
    Sponsor:   Hoffmann-La Roche
    Active, not recruiting
  • Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
    NCT02311933
    Conditions:   Recurrent Breast Carcinoma;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Tamoxifen Citrate;   Drug: Z-Endoxifen Hydrochloride
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease
    NCT02240108
    Condition:   Crohn's Disease
    Interventions:   Drug: Rifaximin EIR;   Drug: Placebo
    Sponsors:   Bausch Health Americas, Inc.;   Salix Pharmaceuticals, Inc. a division of Bausch Health US, LLC
    Terminated
  • Optisure Lead Post Approval Study
    NCT02235545
    Conditions:   Heart Failure;   Tachycardia, Ventricular
    Intervention:   Device: St. Jude Medical Optisure Lead
    Sponsor:   Abbott Medical Devices
    Active, not recruiting
  • Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
    NCT02224781
    Conditions:   Metastatic Melanoma;   Recurrent Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma
    Interventions:   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Biological: Ipilimumab;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Drug: Trametinib;   Drug: Trametinib Dimethyl Sulfoxide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery
    NCT02196181
    Conditions:   BRAF V600E Mutation Present;   BRAF V600K Mutation Present;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Melanoma
    Interventions:   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Drug: Trametinib;   Drug: Trametinib Dimethyl Sulfoxide
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History
    NCT02155660
    Condition:   Moderate to Very Severe Chronic Obstructive Pulmonary Disease
    Interventions:   Drug: Benralizumab Arm A;   Drug: Benralizumab Arm B;   Drug: Benralizumab Arm C;   Drug: Placebo
    Sponsors:   AstraZeneca;   MedImmune LLC
    Completed
  • Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia
    NCT02104817
    Condition:   Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)
    Interventions:   Drug: Epanova® (omega-3 carboxylic acids);   Drug: corn oil control
    Sponsors:   AstraZeneca;   The Cleveland Clinic;   IQVIA RDS Inc.
    Active, not recruiting
  • Mild and Rapidly Improving Stroke Study
    NCT02072681
    Condition:   Ischemic Stroke
    Intervention:  
    Sponsors:   University of Miami;   American Heart Association
    Active, not recruiting
  • A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
    NCT02019264
    Conditions:   Cardiovascular Disease;   High Cardiovascular Risk;   Obesity;   Overweight;   Type 2 Diabetes
    Interventions:   Drug: Lorcaserin hydrochloride;   Drug: Placebo
    Sponsors:   Eisai Inc.;   Thrombolysis In Myocardial Infarction (TIMI) Academic Research Organization
    Completed
  • A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)
    NCT01945775
    Conditions:   Breast Neoplasms;   BRCA 1 Gene Mutation;   BRCA 2 Gene Mutation
    Interventions:   Drug: talazoparib;   Drug: Physician's-Choice
    Sponsors:   Pfizer;   Medivation, Inc.
    Active, not recruiting
  • Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)
    NCT01919697
    Condition:   Chronic Idiopathic Constipation
    Intervention:   Drug: Plecanatide
    Sponsors:   Bausch Health Americas, Inc.;   Syneos Health
    Completed
  • Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
    NCT01896232
    Conditions:   Secondary Hyperparathyroidism;   Chronic Kidney Disease
    Interventions:   Drug: Etelcalcetide;   Drug: Cinacalcet;   Drug: Oral Placebo;   Drug: Intravenous Placebo
    Sponsor:   Amgen
    Completed
  • Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
    NCT01872975
    Conditions:   Stage IB Breast Cancer;   Stage II Breast Cancer
    Interventions:   Radiation: regional nodal XRT;   Radiation: chestwall XRT;   Radiation: WBI
    Sponsors:   NSABP Foundation Inc;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group
    Recruiting
  • Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
    NCT01764633
    Condition:   Dyslipidemia
    Interventions:   Biological: Evolocumab;   Drug: Placebo
    Sponsor:   Amgen
    Completed
  • A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)
    NCT01740427
    Condition:   Breast Neoplasms
    Interventions:   Drug: PD-0332991;   Drug: Letrozole;   Drug: Placebo
    Sponsor:   Pfizer
    Active, not recruiting
  • Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry
    NCT01729455
    Condition:   Systemic Lupus Erythematosus
    Interventions:   Biological: BENLYSTA;   Other: SLE treatment
    Sponsors:   Human Genome Sciences Inc., a GSK Company;   GlaxoSmithKline
    Recruiting
  • VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
    NCT01666444
    Conditions:   Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
    Interventions:   Drug: pegylated liposomal doxorubicin (PLD);   Drug: VTX-2337;   Drug: Placebo
    Sponsors:   Celgene;   Gynecologic Oncology Group
    Completed
  • Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer
    NCT01622868
    Conditions:   HER2 Positive Breast Carcinoma;   Invasive Breast Carcinoma;   Metastatic Malignant Neoplasm in the Brain;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer AJCC v6 and v7
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Lapatinib Ditosylate;   Radiation: Stereotactic Radiosurgery;   Radiation: Whole-Brain Radiotherapy
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Active, not recruiting
  • Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
    NCT01609790
    Conditions:   Giant Cell Glioblastoma;   Glioblastoma;   Gliosarcoma;   Oligodendroglioma;   Recurrent Brain Neoplasm;   Recurrent Glioblastoma
    Interventions:   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Placebo Administration;   Biological: Trebananib
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Active, not recruiting
  • S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer
    NCT01498289
    Conditions:   Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Cancer;   Gastric Cancer
    Interventions:   Drug: FOLFOX regimen;   Drug: docetaxel;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: oxaliplatin
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Completed
  • GLORIA-AF Registry Program - Second and Third Phases
    NCT01468701
    Conditions:   Stroke;   Atrial Fibrillation
    Intervention:  
    Sponsor:   Boehringer Ingelheim
    Active, not recruiting
  • Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
    NCT01281852
    Conditions:   Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Recurrent Cervical Carcinoma;   Stage IVB Cervical Cancer AJCC v6 and v7
    Interventions:   Drug: Cisplatin;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Drug: Veliparib
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Completed
  • A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)
    NCT01369355
    Conditions:   Crohn's Disease;   Colitis;   IBD;   Inflammatory Bowel Disease
    Interventions:   Drug: Placebo SC;   Drug: Placebo IV;   Drug: Ustekinumab 90 mg SC q8w;   Drug: Ustekinumab 130 mg IV;   Drug: Ustekinumab 90 mg SC q12w
    Sponsor:   Janssen Research & Development, LLC
    Completed
  • Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
    NCT01368588
    Condition:   Prostate Cancer
    Interventions:   Radiation: radiation therapy;   Radiation: Whole-pelvic radiotherapy (WPRT)
    Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI);   NRG Oncology
    Active, not recruiting
  • PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
    NCT01333033
    Conditions:   Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Cancer
    Interventions:   Drug: Oxaliplatin;   Drug: Leucovorin Calcium;   Drug: Fluorouracil;   Drug: Carboplatin;   Drug: Paclitaxel;   Procedure: Positron Emission Tomography;   Procedure: Computed Tomography;   Radiation: Radiation Therapy
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Active, not recruiting
  • Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
    NCT01305213
    Conditions:   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
    Interventions:   Biological: Bevacizumab;   Drug: Fosbretabulin Tromethamine;   Other: Laboratory Biomarker Analysis
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Completed
  • Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
    NCT01196390
    Conditions:   Esophageal Adenocarcinoma;   Gastroesophageal Junction Adenocarcinoma;   Stage IB Esophageal Cancer AJCC v7;   Stage IIA Esophageal Cancer AJCC v7;   Stage IIB Esophageal Cancer AJCC v7;   Stage IIIA Esophageal Cancer AJCC v7;   Stage IIIB Esophageal Cancer AJCC v7
    Interventions:   Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment;   Radiation: Radiation Therapy;   Procedure: Therapeutic Conventional Surgery;   Biological: Trastuzumab
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Active, not recruiting
  • QuickFlex Micro Left Ventricular Lead Post Approval Study
    NCT01179477
    Condition:   Heart Failure
    Intervention:   Device: Implantation of a QuickFlex® μ Model 1258T LV Lead
    Sponsor:   Abbott Medical Devices
    Completed
  • Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
    NCT01167712
    Conditions:   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Ovarian Brenner Tumor;   Ovarian Clear Cell Adenocarcinofibroma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Ovarian Undifferentiated Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Stage IIA Fallopian Tube Cancer AJCC v6 and v7;   Stage IIA Ovarian Cancer AJCC V6 and v7;   Stage IIB Fallopian Tube Cancer AJCC v6 and v7;   Stage IIB Ovarian Cancer AJCC v6 and v7;   Stage IIC Fallopian Tube Cancer AJCC v6 and v7;   Stage IIC Ovarian Cancer AJCC v6 and v7;   Stage IIIA Fallopian Tube Cancer AJCC v7;   Stage IIIA Ovarian Cancer AJCC v6 and v7;   Stage IIIA Primary Peritoneal Cancer AJCC v7;   Stage IIIB Fallopian Tube Cancer AJCC v7;   Stage IIIB Ovarian Cancer AJCC v6 and v7;   Stage IIIB Primary Peritoneal Cancer AJCC v7;   Stage IIIC Fallopian Tube Cancer AJCC v7;   Stage IIIC Ovarian Cancer AJCC v6 and v7;   Stage IIIC Primary Peritoneal Cancer AJCC v7;   Stage IV Fallopian Tube Cancer AJCC v6 and v7;   Stage IV Ovarian Cancer AJCC v6 and v7;   Stage IV Primary Peritoneal Cancer AJCC v7
    Interventions:   Biological: Bevacizumab;   Drug: Carboplatin;   Procedure: Computed Tomography;   Drug: Paclitaxel;   Procedure: Therapeutic Conventional Surgery
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Active, not recruiting
  • Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea
    NCT01130272
    Condition:   Irritable Bowel Syndrome
    Interventions:   Drug: Eluxadoline;   Drug: Placebo
    Sponsor:   Furiex Pharmaceuticals, Inc
    Completed
  • Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery
    NCT01013649
    Conditions:   Pancreatic Acinar Cell Carcinoma;   Pancreatic Ductal Adenocarcinoma;   Pancreatic Intraductal Papillary-Mucinous Neoplasm;   Stage I Pancreatic Cancer AJCC v6 and v7;   Stage IA Pancreatic Cancer AJCC v6 and v7;   Stage IB Pancreatic Cancer AJCC v6 and v7;   Stage II Pancreatic Cancer AJCC v6 and v7;   Stage IIA Pancreatic Cancer AJCC v6 and v7;   Stage IIB Pancreatic Cancer AJCC v6 and v7
    Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Capecitabine;   Drug: Chemotherapy;   Drug: Erlotinib Hydrochloride;   Drug: Fluorouracil;   Drug: Gemcitabine Hydrochloride;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Active, not recruiting
  • Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
    NCT00843882
    Conditions:   Anemia;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Myelodysplastic Syndrome
    Interventions:   Biological: Epoetin Alfa;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Study Evaluating Long-Term Safety of MOA-728 in Participants With Opioid-Induced Constipation
    NCT00804141
    Condition:   Constipation
    Intervention:   Drug: N-methylnaltrexone bromide (MOA-728)
    Sponsors:   Bausch Health Americas, Inc.;   Pfizer
    Completed
  • Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
    NCT00803062
    Conditions:   Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma;   Recurrent Cervical Carcinoma;   Stage IVB Cervical Cancer
    Interventions:   Biological: Bevacizumab;   Drug: Cisplatin;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Topotecan Hydrochloride
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Completed
  • A Trial Of [S,S]-Reboxetine In Patients With Chronic Painful Diabetic Peripheral Neuropathy.
    NCT00625833
    Condition:   Diabetic Neuropathies
    Interventions:   Drug: Placebo;   Drug: [S,S]-Reboxetine
    Sponsor:   Pfizer
    Terminated
  • Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer
    NCT00601900
    Conditions:   Invasive Breast Carcinoma;   Recurrent Breast Carcinoma;   Stage III Breast Cancer AJCC v6;   Stage IV Breast Cancer AJCC v6 and v7
    Interventions:   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Other: Questionnaire Administration;   Drug: Tamoxifen Citrate
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain
    NCT00547586
    Condition:   Constipation
    Interventions:   Drug: N-methylnaltrexone bromide (MOA-728);   Other: placebo
    Sponsors:   Bausch Health Americas, Inc.;   Progenics Pharmaceuticals, Inc.
    Completed
  • High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
    NCT00533949
    Conditions:   Lung Cancer;   Radiation Toxicity
    Interventions:   Biological: Cetuximab;   Drug: Carboplatin;   Drug: Paclitaxel;   Radiation: 60 Gy RT;   Radiation: 74 Gy RT
    Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   Cancer and Leukemia Group B;   NRG Oncology
    Active, not recruiting
  • Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain
    NCT00529087
    Condition:   Constipation
    Interventions:   Drug: N-methylnaltrexone bromide (MOA-728);   Other: placebo
    Sponsors:   Bausch Health Americas, Inc.;   Progenics Pharmaceuticals, Inc.
    Completed
  • A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)
    NCT00476996
    Condition:   Rheumatoid Arthritis
    Interventions:   Drug: Leflunomide;   Drug: Methotrexate;   Drug: Ocrelizumab;   Drug: Placebo
    Sponsors:   Genentech, Inc.;   Roche Pharma AG
    Terminated
  • Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive
    NCT00390455
    Conditions:   Estrogen Receptor Positive;   HER2 Positive Breast Carcinoma;   HER2/Neu Negative;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7
    Interventions:   Drug: Fulvestrant;   Other: Laboratory Biomarker Analysis;   Drug: Lapatinib Ditosylate;   Other: Placebo
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer
    NCT00309985
    Condition:   Metastatic Hormone-sensitive Prostate Cancer
    Interventions:   Drug: androgen-deprivation therapy;   Drug: docetaxel
    Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome
    NCT00269412
    Condition:   Irritable Bowel Syndrome
    Intervention:   Drug: Rifaximin
    Sponsor:   Bausch Health Americas, Inc.
    Completed
  • Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
    NCT00262847
    Conditions:   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Brenner Tumor;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Adenocarcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
    Interventions:   Biological: Bevacizumab;   Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Placebo;   Other: Quality-of-Life Assessment
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Completed
  • S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer
    NCT00070564
    Condition:   Breast Cancer
    Interventions:   Biological: pegfilgrastim;   Drug: AC regimen;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • Medical Optimization of Management of Type 2 Diabetes Complicating Pregnancy (MOMPOD)
    NCT02932475
    Conditions:   Diabetes;   Pregnancy
    Interventions:   Drug: Metformin;   Drug: Placebo
    Sponsors:   University of North Carolina, Chapel Hill;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting
  • Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants
    NCT04126213
    Condition:   Respiratory Syncytial Virus Infections
    Interventions:   Biological: RSVPreF3 formulation 2;   Biological: RSVPreF3 formulation 3;   Drug: Placebo
    Sponsor:   GlaxoSmithKline
    Recruiting
  • Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis
    NCT03863574
    Condition:   Non Alcoholic Steatohepatitis
    Interventions:   Drug: Saroglitazar Magnesium 2mg;   Drug: Saroglitazar Magnesium 4mg;   Drug: Placebos
    Sponsor:   Zydus Discovery DMCC
    Recruiting
  • Prosthetic Fit Assessment in Transtibial Amputees Secondary to Trauma
    NCT02540681
    Condition:   Traumatic Amputation of Lower Extremity
    Intervention:  
    Sponsors:   Major Extremity Trauma Research Consortium;   University of California, San Francisco
    Active, not recruiting
  • A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
    NCT03886220
    Condition:   Uterine Fibroids
    Interventions:   Drug: Elagolix;   Drug: Placebo
    Sponsor:   AbbVie
    Recruiting
  • A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Subjects With Comorbid Major Depressive Disorder and Insomnia
    NCT03771664
    Conditions:   Major Depressive Disorder;   Insomnia
    Interventions:   Drug: SAGE-217;   Drug: Placebo
    Sponsor:   Sage Therapeutics
    Recruiting

Popular Now

  • Privacy Policy
  • Ad and Cookie Policy
  • Infringement Policy
  • Terms of Use
  • Email Policy
  • Contact Us
  • Post Clinical Trials
  • Join Clinical Trials
  • Volunteer Login
  • Recruiters Login
  • Frequently Asked Questions
  • Blog
  • Find Clinical Trials
  • Find Volunteers
  • Trials by Category
  • Trials by Location
  • Volunteers by Category
  • Volunteers by Location
All clinical trials are registered and certified with clinicaltrials.gov. Data via U.S. National Library of Medicine,U.S. National Institutes of Health, U.S. Department of Health & Human Services. JoinClinicaltrials.com (Aunica Media llc) is a free resource that provides individuals and companies with information regarding clinical trials that are being conducted nationwide. Aunica Media llc does not conduct clinical trials nor endorses them. Please consult your doctor or physician before participating. And Ye shall know the truth, and the truth shall make you free
©2001-2019 Aunica Media LLC